A detailed history of Seven Mile Advisory transactions in Eli Lilly & CO stock. As of the latest transaction made, Seven Mile Advisory holds 1,136 shares of LLY stock, worth $915,775. This represents 0.76% of its overall portfolio holdings.

Number of Shares
1,136
Previous 1,092 4.03%
Holding current value
$915,775
Previous $850 Million 20.96%
% of portfolio
0.76%
Previous 0.64%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$724.87 - $909.04 $31,894 - $39,997
44 Added 4.03%
1,136 $1.03 Billion
Q1 2024

May 08, 2024

BUY
$592.2 - $792.28 $18,950 - $25,352
32 Added 3.02%
1,092 $850 Million
Q4 2023

Feb 09, 2024

BUY
$525.19 - $619.13 $29,935 - $35,290
57 Added 5.68%
1,060 $618 Million
Q3 2023

Nov 13, 2023

BUY
$434.7 - $599.3 $14,779 - $20,376
34 Added 3.51%
1,003 $539 Million
Q2 2023

Aug 08, 2023

BUY
$350.74 - $468.98 $339,867 - $454,441
969 New
969 $454 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $766B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Seven Mile Advisory Portfolio

Follow Seven Mile Advisory and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Mile Advisory, based on Form 13F filings with the SEC.

News

Stay updated on Seven Mile Advisory with notifications on news.